Clinical Trials Directory

Trials / Unknown

UnknownNCT00219869

Galantamine in the Treatment of Post-Traumatic Headache

Galantamine in the Preventive Treatment of Chronic Post-Traumatic Headache

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
30 (planned)
Sponsor
Rapoport, Alan, M.D. · Individual
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

Most patients with CPTH present with additional major cognitive, behavioral and somatic problems. Most drugs used currently have a negative influence on cognition. Therefore, treatment strategies addressing both the headache and cognitive disturbances in patients with CPTH are necessary. (CPTH; Chronic Post Traumatic Headache).

Detailed description

Headache is the most common symptom after a closed head injury, persisting for more then 2 months in 60% of the patients. CPTH is an important cause of consultations in neurology offices and headache clinics, posing a severe burden and affecting the quality of life of sufferers.

Conditions

Interventions

TypeNameDescription
DRUGGalantamine

Timeline

Start date
2005-07-01
Completion
2005-08-01
First posted
2005-09-22
Last updated
2005-09-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00219869. Inclusion in this directory is not an endorsement.